Arcutis Biotherapeutics Azioni (NASDAQ: ARQT)

Ultime notizie per Arcutis Biotherapeutics (NASDAQ:ARQT) Azioni

ARCUTIS BIOTHERAPEUTICS INC

Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Elevate,Healthcare,With,Ai,Technology,Services.virtual,Health,Care,Analytics,Empower

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

ARQT

TNXP

L&#39;analisi tecnica rivela segnali di allarme per queste società: cosa devono aspettarsi gli investitori e perché è importante agire.

2 titoli del settore sanitario che potrebbero crollare questo trimestre

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics Inc

EFSH

1847 Holdings 2024 Sales $15.7M Up From $14.2M YoY

Guidance

SMXT

SolarMax Technology 2024 EPS $(0.79) Down From $0.01 YoY, Sales $23M Down From $54.1M YoY

Cash and investments at December 31, 2024 of $8.9 million, together with the private placement financing recently announced of up to $14.8 million, expected to provide capital through target completion of the&nbsp;NEPHRO study in the fourth quarter of 2025.
 &nbsp;

TLPH

Talphera Expects Registrational NEPHRO CRRT Study To Be Completed By The End Of 2025

The Company believes that it has access to capital to fund its operations, complete the construction of its ongoing projects, and reach positive adjusted EBITDA in the third quarter of 2025.
The outlook reflects the company's ongoing product mix transition at its Texas facility, which created a temporary decrease in total capacity within its second three acres that is expected to be resolved in the second quarter.
 &nbsp;
 &nbsp;

LOCL

Local Bounti Expects Q1 Sales Of $11.5M (Est $14M)

Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) has outperformed the market over the past 15 years by 1.71% on an annualized basis producing an average annual return of 12.57%. Currently, Royal Caribbean Gr has a market capitalization of $55.29 billion. 
Buying $100 In RCL: If an investor had bought $100 of RCL stock 15 years ago, it would be worth $596.52 today based on a price of $205.44 for RCL at the time of writing.
<h3>Royal Caribbean Gr's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743457513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Royal Caribbean Gr 15 Years Ago Would Be Worth This Much Today

Also concurrent with the Transaction, the Board has named two new Directors, who will replace seats vacated by Edward Forst and Jennifer Carr-Smith. &nbsp;

Management

Local Bounti Says It Secured $25M Investment From New And Existing Investors In March 2025; Craig Hurlbert Steps Into New Role As Executive Chairman, Kathleen Valiasek Named As CEO

The anticipated revenue growth is expected to increase gross profits by an estimated $1.4 million for fiscal year 2025.&nbsp;

XPON

Expion360 Anticipates New OEM Partnerships And Distributors To Generate Incremental Revenue Of $5M For FY25

Soho House (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $0.03 by 1666.67 percent. The company reported quarterly sales of $305.55 million which missed the analyst consensus estimate of $318.36 million by 4.02 percent. This is a 5.08 percent increase over sales of $290.79 million the same period last year.

Earnings

Earnings Misses

SHCO

Soho House Q4 2024 Sales $305.55M Miss $318.36M Estimate

The Company's Class A common stock will begin trading on a reverse-split-adjusted basis when the markets open on April 3, 2025.&nbsp;

Stock Split

MKTW

MarketWise Plans To Effect 1-For-20 Reverse Stock Split Of Its Common Stock

<a href="https://www.youtube.com/watch?v=vqR9UibseME" title="https://www.youtube.com/watch?v=vqR9UibseME">https://www.youtube.com/watch?v=vqR9UibseME</a>

Events

INTC

Intel CEO Lip-Bu Tan, Speaking At  Intel Vision 2025, Said Company Will Spin Off Non-Core Businesses, Plans To Develop Custom Silicon For Specific Applications

CaliberCos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWD#NASDAQ">CWD</a>) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.04) by 1175 percent. This is a 363.64 percent decrease over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $8.69 million which beat the analyst consensus estimate of $6.69 million by 29.85 percent. This is a 63.72 percent decrease over sales of $23.95 million the same period last year.

Earnings Beats

CaliberCos Q4 2024 GAAP EPS $(0.51) Misses $(0.04) Estimate, Sales $8.69M Beat $6.69M Estimate

CPI Aerostructures Q4 EPS, Excluding Deferred Tax Asset Valuation Impact, $0.11 Up From $0.05 YoY, Sales $21.8M Down From $23.5M YoY

The Ordinary Shares have been approved for listing on the NASDAQ Capital Market and are expected to commence trading on April 1, 2025, under the ticker symbol "ENGS."

IPOs

Energys Group Prices IPO Of 2.25M Ordinary Shares At $4.50 Per Ordinary Share

Banco Macro Appoints Juan Parma As Its New CEO

Maui Land & Pineapple 2024 EPS $(0.38) Down From $(0.15) YoY, Sales $11.56M Up From $9.29M YoY

These certifications will enable Springview Singapore to bid for small-scale public sector projects and the Company therefore expects that these certifications will allow Springview Singapore to significantly expand its addressable market.

SPHL

Springview's Singapore Subsidiary Secures Two New Important Government Certifications

GCTK

Glucotrack 2024 EPS $(68.44) Down From $(34.18) YoY

Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) has outperformed the market over the past 20 years by 5.89% on an annualized basis producing an average annual return of 13.93%. Currently, Union Pacific has a market capitalization of $141.58 billion. 
Buying $1000 In UNP: If an investor had bought $1000 of UNP stock 20 years ago, it would be worth $13,730.89 today based on a price of $236.24 for UNP at the time of writing.
<h3>Union Pacific's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743455708_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) reported quarterly losses of $(0.01) per share. This is a 75 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $113.39 million which beat the analyst consensus estimate of $91.88 million by 23.41 percent. This is a 8.43 percent increase over sales of $104.58 million the same period last year.

MVST

Microvast Holdings Q4 2024 Adj EPS $(0.01) Up From $(0.04) YoY, Sales $113.39M Beat $91.88M Estimate

REBN

Reborn Coffee Q4 Sales $1.8M Up From $1.4M YoY

Press Releases

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Health Care

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

General

U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age

Comments

Arcutis Biotherapeutics

Notizie

Ultime notizie per Arcutis Biotherapeutics (NASDAQ:ARQT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO